SCHEMBL8253255

SCHEMBL8253255

CN(C)c1cc(Nc2ccc(SC(F)(F)F)c(Cl)c2)nc(N2CCN(c3cccc(Cl)c3)CC2)n1

nearest known ligand 0.41

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.41
MAPT P10636 3/20 0.38
POLB P06746 2/20 0.38
NPSR1 Q6W5P4 1/20 0.38
SCN9A Q15858 1/20 0.38
CCNE1 P24864 1/20 0.37
CDK2 P24941 1/20 0.37
GAA P10253 1/20 0.36
GFER P55789 1/20 0.36
GALR2 O43603 2/20 0.35
GALR1 P47211 2/20 0.35
CYP3A4 P08684 2/20 0.35
CYP2C9 P11712 2/20 0.35
FGFR3 P22607 1/20 0.35
CYP2C19 P33261 1/20 0.35
PIK3CA P42336 1/20 0.34
LCK P06239 1/20 0.34
HTT P42858 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8253239 0.87 POLB (0.39) LMNAMAPTPOLBNPSR1GALR2
SCHEMBL8253240 0.86 LMNA (0.47) LMNAMAPTPOLBNPSR1SCN9A
SCHEMBL3240505 0.84 MAPT (0.39) LMNAMAPTPOLBNPSR1GAA
SCHEMBL8256719 0.82 LMNA (0.48) LMNAMAPTPOLBNPSR1SCN9A
SCHEMBL8256922 0.81 LMNA (0.47) LMNAMAPTSCN9ACCNE1CDK2
SCHEMBL8253233 0.79 LMNA (0.44) LMNAMAPTNPSR1SCN9ACCNE1
SCHEMBL6710674 0.78 GALR2 (0.55) LMNAMAPTSCN9ACDK2GALR2
SCHEMBL8256647 0.76 CCNE1 (0.42) LMNAMAPTNPSR1SCN9ACCNE1
SCHEMBL8254234 0.76 MAPT (0.47) LMNAMAPTPOLBNPSR1SCN9A
SCHEMBL8253262 0.73 MAPT (0.44) LMNAMAPTPOLBNPSR1SCN9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040082587-A1 2,4,6-Triaminopyrimidines for the treatment of depression and/or anxiety H. LUNDBECK A/S (DK) 2004-04-29 US disclosed
US-20040082587-A1 2,4,6-Triaminopyrimidines for the treatment of depression and/or anxiety H. LUNDBECK A/S (DK) 2004-04-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040082587-A1 2,4,6-Triaminopyrimidines for the treatment of depression and/or anxiety GALR3, GALR2, GALR1 LMNA 3975/4885MAPT 2638/4885POLB 2882/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.